华海药业：2025年净利同比预降70%至80%

Core Viewpoint - Huahai Pharmaceutical (600521) expects a significant decline in net profit attributable to shareholders for the fiscal year 2025, projecting a range between 224 million to 335 million yuan, representing a year-on-year decrease of 70% to 80% [1] Group 1: Financial Performance - The company anticipates a net profit decline due to intensified competition in the existing product market and the slow ramp-up of new products, leading to a decrease in domestic formulation sales revenue year-on-year [1] - The sales revenue of raw materials is also expected to decline year-on-year, impacted by the underperformance of new project industrialization [1] Group 2: R&D and Innovation - The company is accelerating the progress of its biopharmaceutical innovation projects, resulting in a significant year-on-year increase in R&D investment [1]